The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

[1]  B. Decallonne,et al.  Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey , 2020, Journal of Endocrinological Investigation.

[2]  E. Çakal,et al.  The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism , 2020, Archives of Osteoporosis.

[3]  J. Bollerslev,et al.  Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13‐country patient and caregiver survey , 2019, Clinical endocrinology.

[4]  C. Gip,et al.  Defining the Characteristics of Chronic Hypoparathyroidism Not Adequately Controlled on Conventional Therapy: Consensus Findings of Three European Delphi Panels , 2019, Advances in Therapy.

[5]  N. Watts,et al.  Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism , 2019, The Journal of clinical endocrinology and metabolism.

[6]  Jipan Xie,et al.  Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review , 2019, Journal of medical economics.

[7]  L. Nelson,et al.  Psychometric evaluation of the hypoparathyroidism symptom diary , 2019, Patient related outcome measures.

[8]  C. Pedone,et al.  Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  P. Donnan,et al.  Increased mortality and morbidity in patients with chronic hypoparathyroidism: A population‐based study , 2018, Clinical endocrinology.

[10]  Susan A. Martin,et al.  Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism , 2016, Advances in Therapy.

[11]  M. Rubin,et al.  Therapy of Hypoparathyroidism with rhPTH(1-84): A Prospective Eight Year Investigation of Efficacy and Safety. , 2019, The Journal of clinical endocrinology and metabolism.

[12]  L. Rejnmark,et al.  Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus , 2018, European journal of endocrinology.

[13]  L. Rejnmark,et al.  Health‐related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism , 2018, Clinical endocrinology.

[14]  C. Marcocci,et al.  Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism , 2018, Journal of Endocrinological Investigation.

[15]  J. Bilezikian,et al.  Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism , 2017, The Journal of clinical endocrinology and metabolism.

[16]  Publisher's Note , 2018, Anaesthesia.

[17]  Z. Punthakee,et al.  An Overview of the Etiology, Clinical Manifestations, Management Strategies and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry (CNHR) , 2017 .

[18]  J. Bilezikian,et al.  Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses. , 2017, Clinical therapeutics.

[19]  L. Rejnmark,et al.  Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Svartberg,et al.  Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway , 2016, The Journal of clinical endocrinology and metabolism.

[21]  D. Dempster,et al.  Presentation of Hypoparathyroidism: Etiologies and Clinical Features. , 2016, The Journal of clinical endocrinology and metabolism.

[22]  J. Bilezikian,et al.  Management of Hypoparathyroidism: Summary Statement and Guidelines. , 2016, The Journal of clinical endocrinology and metabolism.

[23]  S. Cremers,et al.  Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. , 2016, The Journal of clinical endocrinology and metabolism.

[24]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[25]  O. Dekkers,et al.  European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. , 2015, European journal of endocrinology.

[26]  H. Khoury,et al.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia , 2015, Therapeutic advances in hematology.

[27]  M. Rubin,et al.  PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  A. Fuglsang-Frederiksen,et al.  Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial , 2014, Osteoporosis International.

[29]  B. Clarke,et al.  Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  H. Lagast,et al.  Prevalence and Incidence of Hypoparathyroidism in the United States Using a Large Claims Database , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  L. Rejnmark,et al.  Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow‐up study , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  M. Rubin,et al.  The effect of PTH(1-84) on quality of life in hypoparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[33]  S. Cremers,et al.  Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. , 2013, The Journal of clinical endocrinology and metabolism.

[34]  Michael Vrla,et al.  Long-term follow-up of patients with hypoparathyroidism. , 2012, The Journal of clinical endocrinology and metabolism.

[35]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[36]  L. Rejnmark,et al.  The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo‐controlled study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  D. Spigel.  The value of observational cohort studies for cancer drugs. , 2010, Biotechnology healthcare.

[38]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[39]  C. Janson,et al.  Physical activity and quality of life in subjects with chronic disease: Chronic obstructive pulmonary disease compared with rheumatoid arthritis and diabetes mellitus , 2009, Scandinavian journal of primary health care.

[40]  O. Elert,et al.  The Wuerzburg scale: A new classification system for permanent postoperative hypoparathyroidism , 2007, European Surgery.

[41]  B. Allolio,et al.  Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. , 2002, European journal of endocrinology.